T10583 |
Bosutinib D8
|
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
|
|
T6650 |
Sabutoclax
|
Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
|
|
T22378 |
Nilotinib hydrochloride
|
Nilotinib hydrochloride, the hydrochloride salt form of nilotinib, is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
|
|
T12907 |
SIAIS178
|
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
|
|
T10488 |
BCR-ABL-IN-1
|
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
|
|
T34656 |
SKLB 1028
|
SKLB1028 is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. It shows excellent activity in FLT3-driven AML models and considerable potency in CM...
|
|
T14925 |
Cenisertib
|
Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in ...
|
|
T28374 |
PF-06651481-00
|
PF-06651481-00 is a Bosutinib analog and a Bcr-Abl inhibitor.
|
|
T11961 |
MBM-55S
|
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer ce...
|
|
T22303 |
Dasatinib hydrochloride
|
Dasatinib hydrochloride is a highly ATP competitive, potent, orally active inhibitor of dual Src/Bcr-Abl(with Ki values of 16 pM and 30 pM for Src and Bcr-Abl, r...
|
|
T16545 |
Pivanex
|
Pivanex is a derivative of Butyric acid and is an orally active HDAC inhibitor. Pivanex has antimetastic and antiangiogenic properties. Pivanex down-regulates bc...
|
|
T21785 |
AG957
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in ch...
|
|
T11641 |
N-Desmethyl imatinib
|
N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
|
|
T7186 |
CZC-8004
|
CZC-8004 is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
|
|
T4618 |
BGG463
|
BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
|
|
T16750 |
Rigosertib
|
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
|
|
T6348 |
NVP-BHG712
|
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
|
|
T2116 |
AEE788
|
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
|
T4191 |
Multi-kinase inhibitor 1
|
Multi-kinase inhibitor I is a Multi-kinase inhibitor.
|
|
T30855 |
CGP77675
|
CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylat...
|
|
T2094 |
Danusertib
|
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
|
|
T25476 |
Gypsogenin
|
Gypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
|
|
T10799 |
CHMFL-ABL-039
|
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloi...
|
|
T8488 |
GMB-475
|
GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the ...
|
|
T17267 |
XL228
|
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
|
|
T1817 |
GNF-2
|
GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.
|
|
T2070 |
Agerafenib
|
CEP-32496 is a highly potent inhibitor of BRAF.
|
|
T3063 |
PD173955
|
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC...
|
|
T3071 |
Olverembatinib
|
GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
|
|
T1754 |
ZM 306416
|
ZM 306416, a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
|
|
T6057 |
URMC-099
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
|
T2802 |
Nocodazole
|
Nocodazole is a synthetic inhibitor of microtubule polymerization, also inhibits Abl (IC50: 0.21 μM), Abl(E255K, IC50: 0.53 μM) and Abl(T315I, IC50: 0.64 μM) in ...
|
|
T6128 |
PHA-665752
|
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
|
|
T5177 |
Asciminib
|
Asciminib (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
|
|
T3196 |
GNF-7
|
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.
|
|
T2920 |
Berbamine dihydrochloride
|
Berbamine dihydrochloride, a natural compound derived from the Berberis amurensis plant, has been shown to exhibit antitumor activity in several Ys.
|
|
T4053 |
AST 487
|
AST 487 is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
|
|
T2293 |
SGX-523
|
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
|
|
T2372 |
Ponatinib
|
Ponatinib is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
|
|
T2415 |
PP121
|
PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , ...
|
|
T6311 |
Bafetinib
|
Bafetinib (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and ...
|
|
T2147 |
Nilotinib monohydrochloride monohydrate
|
Nilotinib monohydrochloride monohydrate is significantly potent BCR-ABL against, is a second generation tyrosine kinase inhibitor (TKI), and is active against ma...
|
|
T2328 |
Radotinib
|
Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosom...
|
|
T15164 |
DPH
|
DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.
|
|
T1621 |
Imatinib Mesylate
|
Imatinib mesylate is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively...
|
|
T2429 |
Olverembatinib dimesylate
|
GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
|
|
T7861 |
Flumatinib mesylate
|
Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
|
|
T1524 |
Nilotinib
|
Nilotinib is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
|
|
T2640 |
Rebastinib
|
DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT...
|
|
T10800 |
CHMFL-ABL-121
|
CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein).
|
|